Empagliflozin lowers plasma 1,5-AG concentration and increases the neutrophil count. (A-B) The plasma concentration of 1,5-AG was determined before and 3 and 12 months after the start of empagliflozin treatment in 7 patients with GSD1b and 11 healthy controls: (A) median ± quartiles for the patients and controls, and (B) individual patient profiles. (C-D) Neutrophil counts: (C) median ± quartiles for the patients and controls, and (D) individual profiles. (E) Spearman correlation analysis between plasma 1,5-AG concentration and neutrophil count. (F) median ± quartiles of leukocyte count for the patients and controls, and (G) individual patient profiles. (H) Spearman correlation analysis between plasma 1,5-AG concentration and leukocyte count. (I) median ± quartiles of lymphocyte count for the patients and controls, and (J) individual profiles. (K) Spearman correlation analysis between plasma 1,5-AG concentration and lymphocyte count. (L) median ± quartiles of monocytes count for the patients and controls, and (M) individual profiles. (N) Spearman correlation analysis between plasma 1,5-AG concentration and monocyte count. Statistically significant differences between patients and healthy controls (black) were determined by ordinary 1-way analysis of variance (ANOVA) for unpaired data, whereas mixed-effect analysis for paired data was used to compare values 3 and 12 months after the start of empagliflozin treatment with values obtained before the start of treatment (blue). For clarity, only P values <.5 are shown.